Moolec Science Details $100M+ Equity Boost, Supporting Nasdaq Compliance Exception

summarizeSummary

Moolec Science SA disclosed that significant gains from derecognition events, totaling over $100 million, materially improved its balance sheet, providing the basis for Nasdaq Staff's support for a compliance exception until June 29, 2026.

check_boxKey Events

• Nasdaq Staff Memo Supports Compliance Exception

  Nasdaq Staff issued a memorandum to the Nasdaq Hearings Panel, concluding there is sufficient basis to grant Moolec an exception through June 29, 2026, to regain compliance with the stockholders' equity requirement.

• Material Balance Sheet Improvement Noted

  The Staff memo acknowledges a material improvement in Moolec's balance sheet following a series of accounting and corporate events completed during the fourth quarter of 2025.

• Over $100 Million in Derecognition Gains

  Bankruptcy proceedings involving subsidiaries (Bioceres S.A., Bioceres LLC, and Theo I SCSp) led to Moolec losing control, resulting in derecognition gains of approximately $91.0 million, $5.2 million, and $4.6 million, respectively.

• Company Believes It Has Regained Compliance

  These significant gains, along with other accounting adjustments, have substantially increased Moolec's stockholders' equity, leading the company to believe it has regained compliance with Nasdaq's requirement.

auto_awesomeAnalysis

This filing provides critical financial details that underpin the Nasdaq compliance exception previously announced. The derecognition of subsidiaries due to bankruptcy proceedings, while potentially complex, has resulted in over $100 million in accounting gains, dramatically improving Moolec's stockholders' equity. For a micro-cap company, this balance sheet strengthening is a significant positive development, directly addressing a key delisting risk. Investors should monitor the final decision from the Nasdaq Hearings Panel and subsequent financial reports to confirm sustained compliance.